Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer.

Cancer Cell International
Jing ChenAlexander Tobias Teichmann

Abstract

Drug resistance is always a great obstacle in any endocrine therapy of breast cancer. Although the combination of endocrine therapy and targeted therapy has been shown to significantly improve prognosis, refractory endocrine resistance is still common. Dysregulation of the Hippo pathway is often related to the occurrence and the development of many tumors. Targeted therapies of this pathway have played important roles in the study of triple negative breast cancer (TNBC). Targeting the Hippo pathway in combination with chemotherapy or other targeted therapies has been shown to significantly improve specific antitumor effects and reduce cancer antidrug resistance. Further exploration has shown that the Hippo pathway is closely related to endocrine resistance, and it plays a "co-correlation point" role in numerous pathways involving endocrine resistance, including related pathways in breast cancer stem cells (BCSCs). Agents and miRNAs targeting the components of the Hippo pathway are expected to significantly enhance the sensitivity of breast cancer cells to endocrine therapy. This review initially explains the possible mechanism of the Hippo pathway in combating endocrine resistance, and it concludes by recommending endocrine the...Continue Reading

References

Sep 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Grazia ArpinoRichard M Elledge
Mar 14, 2007·Cancer Cell·Michail ShipitsinKornelia Polyak
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian E SmithMitch Dowsett
Dec 26, 2007·The Journal of Biological Chemistry·Yawei HaoXiaolong Yang
Jan 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·Suling LiuMax S Wicha
Mar 29, 2008·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Emma Pennery
Mar 3, 2009·Journal of Mammary Gland Biology and Neoplasia·Ciara S O'BrienRobert B Clarke
Jun 26, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D GreenUNKNOWN Australian New Zealand Breast Cancer Trials Group
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Chad J CreightonJenny C Chang
Jan 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Hai SongYingzi Yang
Sep 13, 2011·The Journal of Steroid Biochemistry and Molecular Biology·Lianguo KangZhao-Yi Wang
Nov 2, 2011·Proceedings of the National Academy of Sciences of the United States of America·Dawang ZhouJoseph Avruch
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Aug 8, 2012·Breast Cancer Research : BCR·Stephan DussMohamed Bentires-Alj
Nov 1, 2012·Cell Cycle·Ling FangBurton B Yang
Jan 24, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·San-Jian YuZhi-Ming Shao
Nov 2, 2013·EMBO Molecular Medicine·Marco PivaMaria d M Vivanco
Feb 7, 2014·International Journal of Cancer. Journal International Du Cancer·Karin BeelenSabine C Linn
Mar 25, 2014·Nature Cell Biology·Giovanni SorrentinoGiannino Del Sal
Jul 22, 2014·International Journal of Cancer. Journal International Du Cancer·Yanlei MaHuanlong Qin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Cold Spring Harbor Perspectives in Biology
Kieran F Harvey, Iswar K Hariharan
Acta Biochimica Et Biophysica Sinica
Peiguo ShiCeshi Chen
Seminars in Cancer Biology
Fu-Long Li, Kun-Liang Guan
© 2021 Meta ULC. All rights reserved